Investors, Amgen agree to resolve tax bill lawsuit for $74M
Amgen agreed to pay $74 million to resolve an investor lawsuit over a $107 billion tax bill.
Amgen
Amgen is one of the world's largest independent biotechnology companies, developing medicines in oncology, cardiovascular disease, inflammation, bone health, neuroscience, and rare disease. Amgen's portfolio includes biologics like Repatha, Prolia/Xgeva, Otezla, Enbrel (ex-North America), Aranesp, Neulasta, and the recent Horizon Therapeutics acquisition adding Tepezza, Krystexxa, and Ubrelvy.
Company Info
Sector:Biologics / Large-molecule biotechnology
Headquarters:Thousand Oaks, California, USA
Founded:1980
Website:www.amgen.com
Recent News
NICE aims to cut funding for Amgen lung cancer drug Lumykras
NICE aims to cut funding for Amgen lung cancer drug Lumykras Lumykras, which is known as Lumakras in some markets, will no longer be covered by the Cancer Drugs Fund, according to the health technology assessment (HTA) agency. Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in England and Wales, saying the decision does not reflect experience with the lung cancer therapy since it was first made available four years ago.
Amgen recalls almost 1 million bottles of heart failure drug over quality issue
Amgen recalls almost 1 million bottles of heart failure drug over quality issue (reported by BioSpace)
Court halts Colorado price cap on Amgen's blockbuster Enbrel
Court halts Colorado price cap on Amgen's blockbuster Enbrel — Endpoints News coverage of biopharma industry developments.
NEJM retracts pivotal data for Amgen's Tavneos
NEJM retracts pivotal data for Amgen's Tavneos — Endpoints News coverage of biopharma industry developments.
Amgen CFO Transition as Peter Griffith Retires, Thomas Dittrich Returns
Amgen CFO Transition as Peter Griffith Retires, Thomas Dittrich Returns.
Viridian may have edge over Amgen in eye drug showdown, analysts argue
Viridian may have edge over Amgen in eye drug showdown, analysts argue. (BioPharma Dive.)
An Important Update Regarding TAVNEOS (avacopan)
An Important Update Regarding TAVNEOS (avacopan).
Leadership Team
TBD
CEO
Careers & Job Openings